Shield 1993.

Methods	Study design: parallel RCT Study duration: June 1986 to January 1991 Study follow‐up: 3 years
Participants	Country: USA Setting: single centre Inclusion criteria: DD kidney transplant recipients Number: treatment group (99); control group (31) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: possessed anti‐mouse Ab; refused the drug
Interventions	Treatment group OKT3: 5 mg IV bolus given in operating theatre after induction and intubation; no further information provided Control No OKT3 Immunosuppression (both groups) MP: dose not reported AZA: dose not reported No patient received CSA within 36 h of the transplant
Outcomes	Death Graft loss DGF
Notes	Records of all kidney transplant recipients analysed: 31 patients LD (no OKT3); all DD transplant recipients received OKT3 intra‐op unless they were ‘randomised’ to non‐OKT3 arm (may not be truly randomised) Authors made decision to include with sensitivity analysis DD only used for our comparisons Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Limited information but no reason for severe imbalance in LD vs DD patients and unequal numbers in intervention and treatment groups. Likely selection bias; possibly post‐hoc report of unpublished RCT
Allocation concealment (selection bias)	High risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unlikely to influence outcomes
Incomplete outcome data (attrition bias) All outcomes	High risk	Percentages given but no actual numbers for survival and no causes of patient or graft loss
Selective reporting (reporting bias)	High risk	Acute rejection not reported
Other bias	Unclear risk	Insufficient information to permit judgement and funding not declared